ライフサイエンスコーパス: decease

1 dually decreased, while HS showed only minor decease.

2 or tropical cassava during sharp temperature decease.

3 splant and terminated when all patients were deceased.

4 am veterans who were alive in the 1980s were deceased.

5 observed SCr in a cohort of living (79) and deceased (67) donor allograft recipients followed up ove

6 n-years of follow-up, 263 study participants deceased, 89 due to CVD.

7 er factors impacting allograft survival from deceased AA kidney donors, APOL1 renal-risk variants wer

8 brain tissues of alcohol-dependent rats and deceased alcoholics, primarily in frontal and striatal a

9 gh-risk population occurred for 45.2% of the deceased and 40.4% of the survivors.

10 at compassionate and respectful care for the deceased and family, listening for and addressing family

11 he impact of the quality of the care for the deceased and for the family, (5) the content and manner

12 s to determine the effect of HLA matching on deceased and LD renal allograft outcomes in pediatric re

13 magnify and modify extant ethical issues in deceased and living donation related to privacy, confide

14 al, 0.32 to 1.01) ml/min per 1.73 m(2) among deceased and living donor kidney transplant recipients,

15 n addressing a diversity of issues including deceased and living organ donation, improving allograft

16 ucted, using variations of the search terms "deceased" and "controls" to identify relevant peer-revie

17 Empirical data from necropsies of deceased animals were then utilised to assess the conseq

18 The eyes of the deceased babies were removed postmortem and were sent to

19 been explored that regulate the clearance of deceased cardiomyocytes by using the classic and reparat

20 s used deceased controls for comparison with deceased cases (n = 95; 70.9%).

21 cates their appropriateness in studies using deceased cases.

22 Deceased CFLD patients had lower platelet counts than th

23 ing child is older and less prominent if the deceased child was either disabled or an infant, suggest

24 Family 1 had one fetus and one deceased child with heterotaxy and complex congenital he

25 trated in postmortem ocular investigation of deceased children using immunohistochemical staining for

26 iew highlights the breadth of research using deceased controls and indicates their appropriateness in

27 The majority of studies used deceased controls for comparison with deceased cases (n

28 Scholarly debate on the use of deceased controls in epidemiologic research continues.

29 The review identified 134 studies using deceased controls published in English between 1978 and

30 sought on study design, rationale for using deceased controls, application of theoretical principles

31 trol selection, and discussion of the use of deceased controls.

32 entation of DCD that enables an expansion of deceased donation (inclusive of DBD).

33 l and ethical issues pertaining to pediatric deceased donation and developed recommendations for poli

34 s the routine provision of opportunities for deceased donation by pediatric patients and conveys an i

35 to inform provision of best practice care in deceased donation for neonates and children.

36 g Unrelated Donor program and development of deceased donation in Iran.

37 Physicians who are focused on deceased donation medicine as part of their practice can

38 Deceased donation medicine involves unique ethical chall

39 ician role might promote ethical practice in deceased donation medicine.

40 tion Society convened a meeting on pediatric deceased donation of organs in Geneva, Switzerland, on M

41 s with voluntary, unpaid programs; associate deceased donation with being poor and marginal in societ

42 Under Share 35, deceased donor (DD) livers are offered regionally to can

43 y anatomy), and (3) a patient simulated by a deceased donor (high-fidelity anatomy).

44 All patients received an allograft from a deceased donor (median donor age, 61.8 years).

45 m 2005 to 2009 after living donor (n=427) or deceased donor (n=548) renal transplant.

46 modeling showed divided-dose-rATG (P=0.019), deceased donor (P=0.003), serious infection (P=0.0.018),

47 waiting list or received a transplant from a deceased donor (waiting-list-or-transplant control group

48 and risk of GF was observed for HLA-DRB1 in deceased donor and living donor transplants.

49 d, in which ALA was administered both to the deceased donor and to the recipients; and (iii) recipien

50 rfusion biopsy associate with outcomes after deceased donor but not living donor renal transplants, t

51 rocortin-3(-) cells were seen in nondiabetic deceased donor control pancreatic islets.

52 gan Sharing database (2002-2011) queried for deceased donor first LT for primary biliary cirrhosis, p

53 ed the outcomes of 5,230 recipients of first deceased donor grafts transplanted during the period of

54 or even in need of, a kidney transplant, and deceased donor initiated chains in which chains are star

55 Replacement of pancreatic beta-cells through deceased donor islet transplantation is a proven therapy

56 The new deceased donor kidney allocation algorithm uses a Kidney

57 In December 2014, a new national deceased donor kidney allocation policy was implemented,

58 y Allocation System (KAS), a major change to deceased donor kidney allocation, was implemented in Dec

59 erstanding of factors that lead to increased deceased donor kidney discard can allow for targeted int

60 haracterized several important predictors of deceased donor kidney discard.

61 to better characterize the risk factors for deceased donor kidney discard.

62 The median waiting time for a deceased donor kidney in 2013 was 3.5 years.

63 ormed a retrospective cohort study of 47 563 deceased donor kidney match-runs from 2007 to 2013.

64 Optimizing deceased donor kidney quality opens new possibilities to

65 ted with the observed SCr in both living and deceased donor kidney recipients, correlation was strong

66 observed SCr was significantly greater among deceased donor kidney recipients, suggesting poorer func

67 zation, graft loss was substantially higher (deceased donor kidney transplant [DDKT] without delayed

68 gan Sharing data from 2003 to 2012 for adult deceased donor kidney transplant candidates was analyzed

69 Data from 61,927 adult recipients of a deceased donor kidney transplant in 1990 to 2012 registe

70 cells were measured by flow cytometry in 76 deceased donor kidney transplant recipients (DGF, n = 18

71 F and graft loss in pediatric and adolescent deceased donor kidney transplant recipients aged 21 year

72 an adult female patient who presented for a deceased donor kidney transplant with incidental finding

73 hospitalization rate and odds of receiving a deceased donor kidney transplant.

74 ealthier recipients and increasing access to deceased donor kidney transplantation (DDKT) for highly

75 nephropathy or ADPKD) than by lower rates of deceased donor kidney transplantation after waitlisting

76 Induction therapy in deceased donor kidney transplantation is costly, with wi

77 within 3 years of transplantation in 19 450 deceased donor kidney transplantation recipients with Me

78 valuate HA effect on HO-1 upregulation after deceased donor kidney transplantation.

79 n donors and matched nondonors who underwent deceased donor kidney transplantation.

80 It used 5% of deceased donor kidney transplanted in 2015.

81 isk of short- and long-term graft failure in deceased donor kidney transplants across the world.

82 for Organ Sharing data, we identified first deceased donor kidney transplants between October 1, 198

83 Living and standard criteria deceased donor kidney transplants provide significant su

84 a retrospective cohort analysis of pairs of deceased donor kidney transplants where 1 kidney was all

85 ers, Shiraz undertakes the largest number of deceased donor kidney transplants, most liver transplant

86 es among recipients who received their first deceased donor kidney transplants.

87 tes who declined IRDs later received non-IRD deceased donor kidney transplants; the median KDPI of th

88 acellular histones in machine perfusates and deceased donor kidney viability.

89 the value of a living donor kidney versus a deceased donor kidney.

90 A significant proportion of procured deceased donor kidneys are subsequently discarded.

91 om 2003 to 2013, we identified recipients of deceased donor kidneys from the same donor in such a way

92 K Transplant Registry data were collected on deceased donor kidneys implanted between November 1, 201

93 , 66.3% of living donor kidneys and 50.7% of deceased donor kidneys received an optimal histology sco

94 The proportion of deceased donor kidneys recovered for transplant but disc

95 We identified 106,160 deceased donor kidneys recovered for transplant from 200

96 iopsy findings at the time of procurement of deceased donor kidneys remain the most common reason cit

97 of histologic classification, outcomes with deceased donor kidneys were inferior to outcomes with li

98 Over the study period, 523 deceased donor kidneys were transplanted through the KFT

99 Deceased donor kidneys with AKI are often discarded for

100 However, 73.2% of deceased donor kidneys with suboptimal histology remaine

101 r each involved party, the prioritization of deceased donor kidneys, the allocation of chain ending k

102 Pediatric kidneys constitute 10% to 12% of deceased donor kidneys.

103 ney transplants and increased utilization of deceased donor kidneys.

104 valent or beneficial alternative to awaiting deceased donor kidneys.

105 standard criteria, and 0% expanded criteria deceased donor KT (39%, 50%, and 11% in nondonors).

106 eceived a first-time live donor KT (LDKT) or deceased donor KT (DDKT) in 1990-2012.

107 nd Thymoglobulin appear equally effective in deceased donor KTRs maintained on tacrolimus/mycophenola

108 We examined deceased donor liver offer acceptance patterns and their

109 nd recipient characteristics associated with deceased donor liver organ offers for children who died

110 etherlands, DCDs were responsible for 30% of deceased donor liver transplant activity in 2015; Austri

111 ective review of 1300 patients who underwent deceased donor liver transplantation was performed.

112 shown that age is not a contraindication for deceased donor liver transplantation.

113 liary complications and graft survival after deceased donor liver transplantation.

114 Around 1600 deceased donor livers are transplanted annually.

115 d of patients aged >/=18 years who underwent deceased donor LT between January 1, 2003, and December

116 All adult deceased donor LTs from January 1, 2010, to March 31, 20

117 edures that included acceptance criteria for deceased donor organ pancreata and critical raw material

118 potentially inhibiting substantial growth in deceased donor organ transplants in Iran.

119 ft tolerance with a protocol compatible with deceased donor organ utilization.

120 gan donation, there is a chronic shortage of deceased donor organs.

121 the need for organ transplant and supply of deceased donor organs.

122 mentation, including the allocation of fewer deceased donor pediatric kidneys to children and stagnat

123 disease but its contribution to the national deceased donor pool is small.

124 Through comparison between the large deceased donor program in Shiraz and other centers in Ir

125 tween paid donation and the development of a deceased donor program.

126 0.04) more likely to experience MDR, as were deceased donor recipients (adjusted hazard ratio [aHR],

127 For deceased donor recipients, RDP was associated with signi

128 ved renal function (2-36 months; P<0.001) in deceased donor recipients.

129 of this study was to compare the outcomes of deceased donor renal allografts preserved with these flu

130 The waiting time for deceased donor renal transplantation in the United State

131 theater that impact significantly on CIT in deceased donor renal transplantation, some of which are

132 raft function (DGF) in patients who received deceased donor renal transplants.

133 In conclusion, this large deceased donor study shows enrichment of hypoxia and com

134 Conversely, identifying the deceased donor tended to induce thoughts of death rather

135 o a 10-year-old child using a decellularized deceased donor trachea repopulated with the recipient's

136 nsplantation should be promoted by expanding deceased donor transplant programs and use of inexpensiv

137 morbidity score of 5 or greater, receiving a deceased donor transplant reduced the mortality risk by

138 posure level with death and graft loss after deceased donor transplantation were also observed.

139 n optimal and suboptimal kidneys only in the deceased donor transplants (P=0.02).

140 s a single-center retrospective study of all deceased donor transplants from 2004 to 2010 (n=359).

141 he expected survival benefits of living over deceased donor transplants were not present in membranop

142 aft survival was compared between living and deceased donor transplants within each glomerulonephriti

143 is not inferior to that of HLA well-matched deceased donor transplants.

144 and implementing the logistical workflow for deceased donor uterus procurement in a deceased multiorg

145 We detail a new approach to deceased donor uterus procurement.

146 and our own initial experience, in which the deceased donor uterus was procured post cross-clamp and

147 tions regarding the most advantageous use of deceased donor versus living donor transplantation for p

148 rs was the primary outcome; placement on the deceased donor waiting list was also examined.

149 en during late adolescence, and differential deceased donor waiting times based on pediatric priority

150 Even after placement on the deceased donor waitlist, there are racial disparities in

151 waiting list, whether or not a kidney from a deceased donor was received.

152 largest recovery of 11 organs from a single deceased donor with the transplantation of face, bilater

153 lls compared with high-fidelity simulations (deceased donor) (Nontechnical Skills video score: 95% CI

154 We analyzed 1,679 adult, deceased donor, single-organ renal transplants occurring

155 s older than 65 years were transplanted with deceased donor, the mortality risk was reduced by 55% (h

156 rs for post-kidney transplantation SSIs were deceased donor, thin ureters at kidney transplantation,

157 splants-1021 with a living donor, 532 with a deceased donor-under our RDP protocol.

158 tation patients who receive the organ from a deceased donor.

159 dney transplants in the United States from a deceased donor.

160 res are readily accomplishable from the same deceased donor.

161 eous compared with waiting for a negative XM deceased donor.

162 Data were extracted for 12 902 deceased-donor kidney alone transplants performed in all

163 hether a patient will receive an offer for a deceased-donor kidney at Kidney Donor Profile Index thre

164 When a deceased-donor kidney is offered to a waitlisted candida

165 Multicenter, prospective study of deceased-donor kidney recipients to compare UNOS-DGF to

166 ant Recipients database who received a first deceased-donor kidney transplant (1995-2013).

167 le-center, observational study involving 319 deceased-donor kidney transplant recipients, we assessed

168 associated with worse allograft survival in deceased-donor kidney transplantation (DDKT) from AA don

169 Deceased-donor kidney transplantation is frequently perf

170 transplants is limited to a small number of deceased-donor kidney transplants from HIV-positive to H

171 Deceased-donor kidney transplants performed at the weeke

172 parable to those achieved nationally for all deceased-donor kidney transplants.

173 For patients waitlisted for a deceased-donor kidney, hospitalization is associated wit

174 d cohort analysis, obtaining data from every deceased-donor kidney-alone transplant procedure perform

175 ients were evaluated, 65% of whom received a deceased-donor kidney.

176 ero' biopsies for 371 consecutive, solitary, deceased-donor kidneys transplanted at our center betwee

177 Assessment of deceased-donor organ quality is integral to transplant a

178 The shortage of deceased-donor organs is compounded by donation metrics

179 larly sensitised patients cases listed for a deceased-donor transplant during that period.

180 ed associations between injury biomarkers in deceased-donor urine and the following outcomes: donor A

181 patients (panel reactive antibody > 80%), a deceased-donor-first strategy was advantageous, but for

182 ew listings (IRR, 1.02; P = 0.003), 100 more deceased donors (IRR, 1.23; P < 0.001), 100 more new dia

183 Kidney transplantation from deceased donors aged 65 years or older is associated wit

184 ir application to the conduct of research on deceased donors and donor organs within the United State

185 atty acid binding protein (L-FABP) from 1304 deceased donors at organ procurement, among whom 112 (9%

186 ysis of the UK Transplant Registry evaluated deceased donors between 2003 and 2013.

187 EOB evaluated, constituting more than 30% of deceased donors coordinated annually by the NEOB.

188 Use of deceased donors for chain-initiating kidneys raises ethi

189 ective as using high-fidelity anatomies from deceased donors for promoting teamwork skills in this le

190 re conservatively 400 unrecognized potential deceased donors in Canada annually.

191 demonstrated a low prevalence of ZIKV among deceased donors in our community.

192 rative data can be used to identify possible deceased donors in the US and could be a data source for

193 act that kidney transplantation from elderly deceased donors is associated with reduced graft and pat

194 re and a concomitant increase on the rate of deceased donors per million population.

195 ated chains in which chains are started with deceased donors rather than altruistic living donors.

196 ation of organs from HIV-positive living and deceased donors to HIV-positive individuals with end-sta

197 Fifty-six kidneys from deceased donors were recruited into the study.

198 The patients received kidneys from deceased donors who tested positive for HIV with the use

199 study was to evaluate the use of livers from deceased donors who were older than 75 years.

200 e than that of transplants from well-matched deceased donors with 0 to 1 HLA mismatch (log rank, P =

201 nsplantation, graft survival of kidneys from deceased donors with 0 to 1 HLA mismatches compares favo

202 The outcomes of recipients of organs from deceased donors with ITP recorded in the UK Transplant R

203 Organs from the 18- to 34-year-old deceased donors with PHS risks (but relatively few medic

204 00 kidneys (>17% of the total recovered from deceased donors) were discarded in 2013, despite evidenc

205 1 genotype differed from the genotype of the deceased donors, allowing us to differentiate liver- fro

206 of 80 or greater that were procured from 338 deceased donors.

207 on and those who waited for transplants from deceased donors.

208 s were compared with those from well-matched deceased donors.

209 s the rest of Iran's other centers were from deceased donors.

210 ients who received kidneys from HIV-positive deceased donors.

211 donation percentage (percentage of possible deceased-donors who become actual donors; range: 20.0-57

212 ly higher density in live versus prematurely deceased females indicating a potentially mutualistic as

213 Ocular tissue samples from the 4 deceased fetuses (2 female, 2 male) ranging from 21.5 to

214 April 30, 2017, ocular tissue samples from 4 deceased fetuses with a diagnosis of CZS from the Nation

215 In a convenience sample of deceased football players who donated their brains for r

216 e neuropathological and clinical features of deceased football players with CTE.

217 Among 202 deceased former football players (median age at death, 6

218 Donors in the older group were mostly women deceased from stroke, and only 3 patients had experience

219 sequenced from lung samples originating from deceased giant pandas all possessed the substitutions V2

220 bserved using tools to clean the corpse of a deceased group member.

221 The deceased had fewer teeth and more oral infections.

222 andomized, open-label, monocenter trial, 160 deceased heart-beating donors were allowed to perform 23

223 val 0.39 - 0.72), effects that translated to deceased hospital length of stay [median hospital length

224 e interval [95% CI], 0.11-0.65) and standard deceased (HR, 0.52; 95% CI, 0.29-0.94) donor kidney tran

225 METHODS AND Small bowel was obtained from deceased humans, cows, and sheep supported with a contin

226 ta, we assessed patients with ovarian cancer deceased in 2000 to 2012 with at least 13 months of cont

227 8 to 395 months), 22 participants (13%) were deceased, including six deaths attributed to a meningiom

228 Three dimensional images of 157 deceased individuals (37 children, 120 skeletally mature

229 at preventing exposure from hospitalised and deceased individuals.

230 For deceased infants (n = 81), genetic disorders were molecu

231 evaluated in 127 normal adrenal glands from deceased kidney donors (age, 9 months to 68 years).

232 in 89 normal kidney samples from living and deceased kidney donors and normal poles of nephrectomies

233 omes in a prospective cohort study involving deceased kidney donors from five organ procurement organ

234 ied enteroadherent EPEC in the intestines of deceased kittens.

235 tion and hemorrhage in the adrenal glands of deceased mice.

236 d paraffin-embedded bone marrow samples from deceased MM patients were stained with LLP2A-Cy5.

237 w for deceased donor uterus procurement in a deceased multiorgan donor setting.

238 worsened (liver transplantation [LT] (n=5), deceased (n=2)).

239 on with DHA as observed in vivo, resulted in deceased Notch 1/Jagged 1 protein expression however, DH

240 implantation, 50.9% of patients were either deceased or in hospice.

241 Outcomes were deceased or living donor transplant, death or removal fr

242 The influence of preference for type of KT (deceased or living donor) and transplant center location

243 Grafts can be obtained from deceased or living donors, with different logistical req

244 Development of strategies to increase deceased organ donation is dependent on timely, accurate

245 idney donation offers superior outcomes over deceased organ donation, but incurs psychosocial and eth

246 from next of kin or family is sought for all deceased organ donation.

247 ere may be significant potential to increase deceased organ donations in Canada.

248 ntions on increasing the willingness to be a deceased organ donor (measured as commitment to donate a

249 m within the residual pancreatic islets of a deceased organ donor who had T1D.

250 Compared with the standard risk deceased organ donor, the PHS donor was younger, male, d

251 rease the willingness of individuals to be a deceased organ donor.

252 intracranial hemorrhage than were all other deceased organ donors (85% vs. 57%, p < 0.001).

253 Our primary outcome measure was potential deceased organ donors (identified by the presence of dia

254 Deceased organ donors are routinely screened for behavio

255 Current screening of deceased organ donors by RPR yields a significant number

256 urrent U.S. policy requires screening of all deceased organ donors for syphilis infection.

257 We identified all UK deceased organ donors from 2003 to 2015 with a disclosed

258 Twenty-one deceased organ donors had a predonation diagnosis of ITP

259 tive was to estimate the number of potential deceased organ donors in Canada.

260 le for 75% of the increase in the numbers of deceased organ donors in the United Kingdom.

261 After the 2013 modification, over 20% of all deceased organ donors in the United States were identifi

262 The number of deceased organ donors remains stable but donor age is in

263 Thirty-two of 3,555 (0.9%) potential deceased organ donors screened during the study period s

264 Positive ZIKV tests in local deceased organ donors were investigated from 6/2016 to 1

265 sequencing (RNA-seq) on islets from multiple deceased organ donors, including children, healthy adult

266 nformation regarding the number of potential deceased organ donors.

267 ath (DCD) provides an alternative pathway to deceased organ transplantation.

268 om 2009-2012, 96,028 (3.3%) were a "possible deceased-organ donor." The two proposed metrics of OPO p

269 over a 24-year period (1988-2012) for 3,238 deceased participants (43.9% men).

270 e study included 286 autopsied brains of 554 deceased participants (51.6%).

271 Cross-sectional analyses of deceased participants in the Memory and Aging Project cl

272 etic, and transcriptional data available for deceased participants of the Religious Orders Study (n =

273 5), parent (3), or other relation (1) of the deceased patient.

274 aseline efflux capacity was not different in deceased patients and survivors (P=0.60 or P=0.50 for ca

275 Deceased patients had fewer teeth (P <0.001) and higher

276 Median time to death for 131 deceased patients was 14 mo; median follow-up of living

277 s, globus pallidus, and thalamus of these 23 deceased patients were harvested and analyzed with induc

278 The charts of deceased patients were reviewed for liver biopsy to eval

279 Methods We interviewed 2,307 families of deceased patients with advanced lung or colorectal cance

280 Of 1490 deceased patients, 620 (41.6%) died of ocular melanoma.

281 mily overrule of donation of solid organs by deceased patients, and examine arguments both in favor o

282 amilies to receive money for donation from a deceased person, who is at no risk of harm, will make it

283 mined published epidemiologic research using deceased persons as a control group.

284 Participants were 1096 deceased persons from two clinical-pathologic studies.

285 l origin of 83% of alleles, and genotypes of deceased recent ancestors for whom no genotype informati

286 who give permission for the removal of their deceased relative's organs for transplantation exist in

287 en asked to consent to the donation of their deceased relative's organs or tissues.

288 donation themselves, donate the organs of a deceased relative, or support a transition to an "opt-ou

289 ion commitment cards, donate the organs of a deceased relative, support the transition to an "opt-out

290 We used a database comprising 1.4 million deceased soldiers to identify war orphans and collect in

291 ars) is worse than younger LD but similar to deceased standard criteria donors (SCD).

292 donors and living donors, as alternatives to deceased standard criteria donors.

293 and pathological data were derived from 607 deceased subjects (mean age at death, 89 years; 66% wome

294 GLS and EF were both more abnormal in deceased than in those alive by day-28 follow-up (both P

295 nd (6) the characteristics of the family and deceased that affect the request for family consent.

296 25 hemodialysis patients who underwent first deceased transplantion.

297 erall survival benefit was 62% versus 70% in deceased versus living donor transplanted patients.

298 FLD (143 versus 258 U/L, P = 0.004) or those deceased with no CFLD (143 versus 327U/L, P = 0.006).

299 ncluded 4256 patients with ALS (3125 [73.4%] deceased) with genotype data extended to 7174392 variant

300 low-up of 49 months), 71.6% of patients were deceased, with median survival time of 11 months for tho